Ascelia Pharma will attend the Jefferies Healthcare Conference.

Julie Waras Brogren will present at Redeye Life Science Day. To register: https://www.redeye.se/events/915984/redeye-life-science-day-2023

Ascelia will present the progress towards headline results of SPARKLE at Redeye.

Magnus Corfitzen will present the full year report 2023. To join register: https://www.inderes.dk/videos/ascelia-pharma-presentation-of-full-year-report-2023

Magnus Corfitzen will be presenting at Penser by Carnegie Company Day. The event will also be livestreamed (in Room 3): https://youtube.com/playlist?list=PLFeVXfrcmwBBZOh_NjsLu2mH3-KYatyIY&si=Vw00086nDtH-rIiL

AGM 2024.

Ascelia Pharma will give an investor update - please see link below to watch the event and send your questions prior to the event: Investor Update - Bringing Orviglance to patients

If you wish to participate via webcast, please use the link below. You can ask written questions through the webcast: https://ir.financialhearings.com/ascelia-pharma-q1-report-2024

Magnus Corfitzen will present the Q1 interim report. To register to the event: Ascelia Pharma - What happened during Q1 2024  

Ascelia Pharma will present at the Carnegie Healthcare Conference.

Ascelia Pharma will present at the HC Andersen Life Science Seminar, to attend: https://www.inderes.dk/videos/life-science-seminar-2024

Julie Waras Brogren, Deputy CEO will present the commercial and partnership strategy for Orviglance, to register and submit your questions: Ascelia Pharma commercial and partnership strategy

Julie Waras Brogren will present the Q2 interim report at a virtual live event for investors. To register:  Update Q2 2024

Magnus Corfitzen will present at Cargenie. The presentation will be live streamed: Ascelia Pharma Live Presentation  

Magnus Corfitzen will present the final outcome of the Rights issue. You can already sign up for the event: Ascelia Pharma Final Outcome Of Rights Issue  

Julie Waras Brogren, Deputy CEO will present Q3 2024 results. To register to the event: Ascelia Pharma - What Happened During Q3 2024